27940951|t|APOBEC3A/B -induced mutagenesis is responsible for 20% of heritable mutations in the TpCpW context
27940951|a|APOBEC3A/B cytidine deaminase is responsible for the majority of cancerous mutations in a large fraction of cancer samples. However, its role in heritable mutagenesis remains very poorly understood. Recent studies have demonstrated that both in yeast and in human cancerous cells, most APOBEC3A/B -induced mutations occur on the lagging strand during replication and on the nontemplate strand of transcribed regions. Here, we use data on rare human polymorphisms, interspecies divergence, and de novo mutations to study germline mutagenesis and to analyze mutations at nucleotide contexts prone to attack by APOBEC3A/B. We show that such mutations occur preferentially on the lagging strand and on nontemplate strands of transcribed regions. Moreover, we demonstrate that APOBEC3A/B -like mutations tend to produce strand-coordinated clusters, which are also biased toward the lagging strand. Finally, we show that the mutation rate is increased 3' of C→G mutations to a greater extent than 3' of C→T mutations, suggesting pervasive trans-lesion bypass of the APOBEC3A/B -induced damage. Our study demonstrates that 20% of C→T and C→G mutations in the TpCpW context-where W denotes A or T, segregating as polymorphisms in human population -or 1.4% of all heritable mutations are attributable to APOBEC3A/B activity.
27940951	0	10	APOBEC3A/B	T028	C3540384
27940951	20	31	mutagenesis	T044	C0079866
27940951	58	67	heritable	T169	C0439660
27940951	68	77	mutations	T045	C0596611
27940951	85	90	TpCpW	T086	C0314659
27940951	99	109	APOBEC3A/B	T028	C3540384
27940951	110	128	cytidine deaminase	T116,T126	C0010723
27940951	164	173	cancerous	T191	C0006826
27940951	174	183	mutations	T045	C0596611
27940951	207	213	cancer	T191	C0006826
27940951	214	221	samples	T167	C0370003
27940951	244	253	heritable	T169	C0439660
27940951	254	265	mutagenesis	T044	C0079866
27940951	344	349	yeast	T004	C0043393
27940951	357	362	human	T016	C0086418
27940951	363	378	cancerous cells	T025	C0334227
27940951	385	395	APOBEC3A/B	T028	C3540384
27940951	405	414	mutations	T045	C0596611
27940951	428	442	lagging strand	T114	C1704973
27940951	450	461	replication	T045	C0598312
27940951	473	491	nontemplate strand	T114	C1704973
27940951	495	514	transcribed regions	T028	C0079941
27940951	542	547	human	T016	C0086418
27940951	548	561	polymorphisms	T045	C0032529
27940951	563	586	interspecies divergence	T045	C0917892
27940951	592	609	de novo mutations	T049	C2985439
27940951	619	639	germline mutagenesis	T045	C0206530
27940951	655	664	mutations	T045	C0596611
27940951	668	678	nucleotide	T114	C0028630
27940951	707	717	APOBEC3A/B	T028	C3540384
27940951	737	746	mutations	T045	C0596611
27940951	775	789	lagging strand	T114	C1704973
27940951	797	816	nontemplate strands	T114	C1704973
27940951	820	839	transcribed regions	T028	C0079941
27940951	871	881	APOBEC3A/B	T028	C3540384
27940951	888	897	mutations	T045	C0596611
27940951	933	941	clusters	T028	C0017258
27940951	976	990	lagging strand	T114	C1704973
27940951	1018	1031	mutation rate	T080	C3178846
27940951	1051	1064	C→G mutations	T045	C0079870
27940951	1096	1109	C→T mutations	T045	C0079870
27940951	1132	1151	trans-lesion bypass	T045	C1158535
27940951	1159	1169	APOBEC3A/B	T028	C3540384
27940951	1179	1185	damage	T049	C0012860
27940951	1222	1225	C→T	T045	C0079870
27940951	1230	1243	C→G mutations	T045	C0079870
27940951	1251	1256	TpCpW	T086	C0314659
27940951	1281	1282	A	T114,T121,T123	C0001413
27940951	1286	1287	T	T114	C0040090
27940951	1304	1317	polymorphisms	T045	C0678951
27940951	1321	1337	human population	T016	C0086418
27940951	1354	1363	heritable	T169	C0439660
27940951	1364	1373	mutations	T045	C0596611
27940951	1394	1404	APOBEC3A/B	T028	C3540384
27940951	1405	1413	activity	T045	C0314627